secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCardia, Inc. (BCDA)
CIK:        0000925741
Form:       8-K
Filed at:   2026-02-10T23:59:59+00:00
Accession:  0001437749-26-003582
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCardia files FDA Pre-Submission for Helix transendocardial catheter approval
-------------------------------------------------------------------------------

- Completed Pre-Submission (Q-Submission) to FDA for Helix catheter for intramyocardial delivery.
- Data from 15 well-controlled clinical trials supports safety and effectiveness.
- Pre-Submission under CardiAMP Cell Therapy System FDA Breakthrough Designation.
- Goal to align with FDA on regulatory pathway and timing within next 45 days.
- CEO states Helix aims to be first approved transendocardial delivery catheter in US.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/925741/000143774926003582/0001437749-26-003582-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/925741/000143774926003582/bcda20260210c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-003582

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer